The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)-phenoxy] ethanamine.HCl, may potentiate doxorubicin in the treatment of metastatic breast cancer: Results of a pilot study

Breast Cancer Research and Treatment

Volumn 49, Issue 1, 1998, Pages 61-68

  Brandes, Lorne J ^a,b,c   Bracken, Susan P ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Manitoba Cancer Treatment and Research Foundation   (Canada)

^c NONE   (Canada)

Author keywords

Breast cancer; Doxorubicin; DPPE; Potentiation

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; DEXAMETHASONE; DOXORUBICIN; RANITIDINE; TESMILIFENE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CARDIOTOXICITY; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; DYSPEPSIA; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VERTIGO; VISUAL HALLUCINATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MIDDLE AGED; MOTION SICKNESS; NAUSEA; PHENYL ETHERS;

EID: 0031867455     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005909808529     Document Type: Article

References (24)

1. Henderson IC: In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds): Breast Diseases, Philadelphia, PA, Lippincott, pp 428-479, 1987
2. Sledge GW: Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 22: Suppl 2, 123-125, 1995
3. Falkson G, Falkson CI, Falkson H: In: Powles TJ, Smith IE (eds) Medical Management of Breast Cancer. London, Martin Dunitz, pp 139-152, 1991
4. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomised trial. J Clin Oncol 13: 2483-2489, 1995
5. de Graaf H, Willemse PHB, de Vries EGE et al.: Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 30A: 150-153, 1994
6. Gianni AM, Siena S, Bregni M et al.: Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 15: 2312-2321, 1997
7. Brandes LJ, Hermonat MW: A diphenylmethane derivative specific for the antiestrogen binding site in rat liver microsomes. Biochem Biophys Res Commun 123: 724-728, 1984
8. 1C) that regulate cell proliferation. Adv Biosci 89: 31-41, 1993
9. LaBella FS, Brandes LJ: Enhancement of tumour growth by drugs with some common molecular actions. Mol Carcinogenesis 16: 68-76, 1996
10. Brandes LJ, LaBella FS, Warrington RC: Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J Natl Cancer Inst 83: 1329-1336, 1991
11. Corbel S, Dy M: Evidence for histamine uptake by murine hematopoietic progenitors. Agents Actions 41: C113-114, 1994
12. Glavin GB, Brandes LJ: Antiulcerogenic and antisecretory effects of a novel diphenylmethane derivative and antiestrogen binding site ligand. Can J Physiol Pharmacol 66: 1139-1143, 1988
13. Brandes LJ, Simons KJ, Bracken SP, Warrington RC: Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl in combination with various single antineoplastic agents. J Clin Oncol 12: 1281-1290, 1994
14. Brandes LJ, Bracken SP, Ramsey EW: N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. J Clin Oncol 13: 1398-1403, 1995
15. Smith EJ, Vogclzang NJ, Goldberg HL et al.: High-dose cyclophosphamide (CTX) with granulocyte-macrophage colony stimulating factor (GM-CSF) in hormone-refractory prostatic cancer. Proc Am Soc Clin Oncol 11: 213 (Abstract), 1992
16. Brandes LJ, MacDonald KA, Bracken SP et al.: Results of human pilot study testing the hypothesis that the intracellular histamine antagonist DPPE increases the therapeutic index of doxorubicin. Adv Biosci 89: 375-401, 1993
17. 2 histamine antagonist. Digestion 47: 143-148, 1990
18. Evans WK, Eisenhauer EA, Cormier Y, et al.: Phase II study of amonafide: Results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. J Clin Oncol 8: 390-395, 1990
19. Pollen JJ, Shlaer WJ: Osteoblastic response to successful treatment of metastatic cancer of the prostate. Am J Roentgenol 132: 927-931, 1979
20. Henderson IC, Canellos GP: Cancer of the breast: the past decade. N Eng J Med 302: 78-80, 1980
21. Ahmann DL, Schaia DJ, Bisel HF, Hahn RG, Edmonson JH, Ingle JN: The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug. J Clin Oncol 5: 1928-1932, 1987
22. Norris B, Pritchard K, James K, et al.: A phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in recurrent/metastatic breast cancer (MBC): A National Cancer Institute of Canada (NCIC CTG) study. Proc Amer Soc Clin Oncol 15: 98, 1996
23. Speyer JL, Green MD, Dubin N, et al.: Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med 78: 555-563, 1985
24. Shapira J, Gottfried M, Lishner M, Ravid M: Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: A prospective randomized evaluation. Cancer 65: 870-873, 1990